About Exact Sciences
What Exact Sciences is building
Company culture
Integrity
We always do the right thing
Innovation
We discover, share and welcome new ideas
Funding rounds
Total Funding
Last funding round type
Company type
Exact Sciences news and updates
Exact Sciences Corporation acquires Invitae Corporation
Social media is speculating about the idea that Exact Sciences would buy Invitae.
Oct 3, 2022 | thestreet.comExact Sciences Corporation invested into assets : genetics lab PreventionGenetics in the amount of $190M on Jan 1st 22'.
In January, Exact Sciences also announced its acquisition of Marshfield-based genetics lab PreventionGenetics for $190 million.
Jan 1, 2022 | madison.comExact Sciences Corporation partners with John Hopkin’s University
Exact Sciences is collaborating with Mayo Clinic, Johns Hopkins University, and the Translational Genomics Research Institute to develop novel detection technologies for disease detection along the cancer care continuum.
Jan 1, 2022 | sdnews.comExact Sciences Corporation partnered with American Society of Clinical Oncology on Apr 28th 22'.
Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score ® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update.
Jan 1, 2022 | biospace.comExact Sciences Corporation acquired OmicEra Diagnostics GmbH on Apr 26th 22'.
In an earnings call with investors on April 26, Exact Sciences chairman and CEO Kevin Conroy mentioned that the company had agreed to acquire OmicEra as he discussed the company's development pipeline, including its efforts to develop a multi-cancer early detection test based on multiple biomarkers.
Jan 1, 2022 | bizjournals.comExact Sciences Corporation partnered with Ascopubs on Apr 28th 22'.
Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence Score® test in early-stage breast cancer patients has been expanded by the American Society of Clinical Oncology (ASCO) in its 2022 Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer guideline update.
Jan 1, 2022 | exactsciences.comExact Sciences Corporation sells assets to MDxHealth Group
MDxHealth SA has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences ( NASDAQ: EXAS ) as well as the latter's urology sales and marketing team.
Jan 1, 2022 | clival.comExact Sciences donates $500k toward Black Business Hub construction
Exact Sciences is investing $500,000 into construction of the Urban League of Greater Madison’s Black Business Hub, the company announced Thursday. Exact Sciences will lease space in the Hub, which will be located on the city’s south side, to connect with job seekers and other community organizations.
Dec 9, 2021 | nbc15New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the importance of adverse pathology as a reliable and critical endpoint for risk-assessment in clinically low-risk prostate cancer patients.
Nov 23, 2021 | Cision PR NewswirePhillips-Medisize, Exact Sciences to collaborate on colorectal cancer screening
Phillips-Medisize and Exact Sciences (NSDQ:EXAS) today announced a collaboration to advance early cancer detection. The collaboration centers around Exact Sciences’ Cologuard, the first and only FDA-approved, non-invasive stool DNA screening test for colorectal cancer, according to a news release.
Nov 3, 2021 | MassDeviceFaith Technologies partners with Exact Sciences Corporation
“Faith Technologies has been proud to partner with Exact Sciences on many of the projects on their growing campus,” said Mike Jansen, CEO of Faith Technologies.
Jan 1, 2021 | wisbusiness.comFight Colorectal Cancer partnered with Exact Sciences Corporation on Feb 1st 21'.
“ACS CAN is grateful for the opportunity to partner with Fight CRC and Exact Sciences to advocate for public policy change at the state level that will help to increase screening rates for colorectal cancer through the Catalyst Grant Program.
Jan 1, 2021 | sciencenewsnet.inHitchwood Capital Management LP invests into Exact Sciences Corporation
Hitchwood Capital Management LP has invested 0.28% in Exact Sciences Corporation (NASDAQ:EXAS).
Jan 1, 2019 | investtribune.comExact Sciences Corporation partners with Mayo Clinic
Working in collaboration with Mayo Clinic, Exact Sciences has identified novel markers and improved laboratory processes to help achieve its performance enhancement goals and has initiated a 10,000-patient prospective study to validate the performance of the enhanced test.
Jan 1, 2019 | streetinsider.comExact Sciences Corporation is developing liquid biopsy test
The focus on Cologuard underpins its importance for Exact as it works to develop a liquid biopsy test for the same purpose.
Jan 1, 2019 | medtechdive.com